Table 1.
Selected reported bromodomain inhibitors tested in models of HIV latency.
| Compound | Model of HIV latency | Effect | Reference |
|---|---|---|---|
| JQ1 | Ach2 | reactivation | [83] |
| JQ1 | U1 | reactivation | |
| JQ1 | J-Lat 10.6 | reactivation | |
| JQ1 | Acutely infected primary CD4+ cells | reactivation | |
| JQ1 | J∆K | reactivation | [84] |
| JQ1 | J-Lat A2 | reactivation | [85] |
| JQ1 | Jurkat 1G5 | reactivation | |
| JQ1 | HeLa NH1 and NH2 | reactivation | |
| JQ1 | HeLa-T4 | reactivation | [86] |
| JQ1 | Primary CD4+ T cells | reactivation | |
| JQ1 | Primary CD4+ T cells | inhibition | |
| JQ1 + Prostratin or PMA | J-Lat 6.3 | reactivation | |
| JQ1 + Prostratin or PMA | J-Lat 8.4 | reactivation | |
| JQ1 + Prostratin or PMA | J-Lat 9.2 | reactivation | |
| JQ1 + Prostratin or PMA | J-Lat 15.4 | reactivation | |
| JQ1 | J-Lat A2 | reactivation | [87] |
| JQ1 | J-Lat A72 | reactivation | |
| JQ1 | infected primary Bc12-transduced CD4+ T cells | reactivation | |
| JQ1 | infected primary nonpolarized T helper cells | no reactivation | |
| I-BET | infected primary Bc12-transduced CD4+ T cells | reactivation | |
| I-BET | infected primary nonpolarized T helper cells | no reactivation | |
| I-Bet151 | J-Lat A2 | reactivation | |
| I-Bet151 | J-Lat A72 | reactivation | |
| I-Bet151 | infected primary Bc12-transduced CD4+ T cells | reactivation | |
| I-Bet151 | infected primary nonpolarized T helper cells | no reactivation | |
| MS417 | J-Lat A2 | reactivation | |
| MS417 | J-Lat A72 | reactivation | |
| MS417 | infected primary Bc12-transduced CD4+ T cells | reactivation | |
| MS417 | infected primary nonpolarized T helper cells | no reactivation |